Drug intelligence / Profile preview

ANY001

Development stage: Unknown
Lead developer: Anya Biopharm
Modality: Peptides
Administration: Oral

Overview

ANY001 is an investigational oral peptide glucagon-like peptide-1 (GLP-1) receptor agonist being developed by Anya Biopharm for the treatment of type 2 diabetes and obesity. The drug is formulated using the company's proprietary Mira/Je® platform, which is designed to enable the oral delivery of peptides that are typically administered via injection by facilitating their absorption through the gastrointestinal tract. ANY001 is currently the lead candidate in Anya's metabolic pipeline; while categorized as being in preclinical development, the company has reported that human pharmacokinetic (PK) results are already available, indicating it has undergone early-stage clinical evaluation.

Other names: Oral GLP1 product A

Targets

GLP1R (GLP-1R)

Beyond the preview

Go deeper on ANY001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ANY001.

Explore the full profile